LPAR1

(redirected from LPA1)

LPAR1

A gene on chromosome 9q31.3 that encodes an endothelial differentiation, G protein-coupled (EDG) family receptor for lysophosphatidic acid, a bioactive lysophospholipid that mediates diverse biologic functions, including proliferation, platelet aggregation, smooth
muscle contraction, inhibition of neuroblastoma cell differentiation, chemotaxis and tumour cell invasion.
References in periodicals archive ?
Deletion of lysophosphatidic acid receptor LPA1 reduces neurogenesis in the mouse dentate gyrus.
To investigate how LPA exerted this effect, the team produced mice that genetically lack one or both of the two receptors -- LPA1 and LPA2 -- to which LPA can bind on ventricle-building fetal progenitor cells, finding that the LPA1 receptor was required to produce hydrocephalus.
announced today that it will present preclinical data on AM152, an LPA1 receptor antagonist, during the Annual Meeting of the American Thoracic Society (ATS) in Denver, Colorado.
69) The G protein-coupled receptors for lysophosphatidic acid, LPA1 and LPA2, which can signal through nuclear factor [kappa]B or Akt, were recently shown by Yamada et al (70) to be expressed in MPM cell lines and human samples, and the addition of LPA enhanced cell proliferation and motility via LPA1 and LPA2, respectively.
Updates on InterMune's small molecule fibrosis research programs, including pirfenidone analogs and inhibitors of LPA1 and LOXL2, will be presented at the meeting.
announced today initial positive data from a Phase 1 clinical study of AM152, the Company's oral selective antagonist of the LPA1 receptor.
Subsequent development work resulted in two DP2 antagonists and an LPA1 antagonist that all completed Phase 1 trials prior to the acquisition of Amira by Bristol-Myers Squibb for a total deal of $475 million.
announced today that AM152, the company's lead LPA1 antagonist, has been granted an orphan drug designation by the U.
The maximum nucleotide/amino acid identity between the LPA1 virus A/Mallard/Sweden/56/02 and A/Turkey/Ireland/PV74/95 (H7NT) was 95% nt, 96% aa; between A/Mallard/Sweden/56/02 and A/England/268/96 (H7N7), it was 96% nt and 97% aa.
Role of Lysophosphatidic Acid and its Receptor LPA1 in Scleroderma Dermal Fibrosis.
We believe there are numerous potential drug targets in this pathway, and our autotaxin inhibitor is the latest in our portfolio of LPA-related drug targets, which also includes our LPA1 receptor antagonist AM152 which is currently in phase 1 clinical trials.